Validating the European LeukemiaNet 2022 Guidelines in a Middle Eastern Acute Myeloid Leukemia Cohort: Correlation
Salem H Alshemmari1, Ahmad AlSarraf2, Reem Ameen3
1Department of Medicine, Kuwait University, Jabriya, State of Kuwait; Department of Hematology, Kuwait Cancer Control Center, Kuwait City, State of Kuwait.
Background:
The European LeukemiaNet (ELN) guidelines are widely used for risk stratification in acutemyeloid leukemia (AML), but validation in non Western patients remains limited.
Materials And Method:
This retrospective study of 227 newly diagnosed AML patients from the Kuwait Cancer Control Center assessed the 2022 and 2017 ELN risk classification systems and their impact on event-free survival (EFS) and overall survival (OS), add ressing the need for diverse population data in AML prognostication.
Results:
Compared to ELN2017, ELN2022 reclassified 14% of patients. Outcomes were effectively discriminated by both ELN2017 (EFS C index 0.607, log rank P < .001; OS C index 0.591, P < 001) and ELN2022 (EFS C index 0.607, P < .001; OS C index 0.590, P < .001). Among 171 patients receiving intensive chemotherapy (IC), ELN2022 was even more discriminative (EFS C index 0.650; OS C index 0.637). Multivariable analyses confirm ELN2022 as an independent predictor of outcomes for the full cohort (EFS 2df Wald P < .001; OS P = .004) and IC subset (EFS P < .001; OS P = .001). Consistent with Western findings, neither ELN system was validated in our subgroup of 28 nonintensively treated patients (for ELN2022, adverse risk had the longest median EFS and OS).
Conclusion:
ELN2022 was an independent predictor of survival in a Middle Eastern AML cohort, particularly for patients receiving IC, validating this prognostic tool in an understudied population.
More Related Videos
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018